You are here: Industry Insights > Novartis

News List

NMPA approves Novartis's Cosentyx for psoriasis patients biospectrumasia
April 03, 2019
Cosentyx is the first biologic approved in China that specifically inhibits interleukin-17A (IL-17A), a cornerstone cytokine involved in the inflammation of psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS)
Novartis to buy IFM Tre for up to $1.57bn pharmaceutical-technology
April 03, 2019
Novartis has agreed to acquire anti-inflammatory group IFM Tre, a subsidiary of IFM Therapeutics, in a deal worth up to $1.57bn.
Novartis seeks to further tap into Chinese healthcare market firstwordpharma
April 03, 2019
Novartis CEO Vas Narasimhan indicated that the drugmaker aims to boost its presence in China by launching new products in the country and enhancing collaborations with local biotechnology and technology firms to...
The AveXis expands world-leading gene therapy manufacturing capacity with purchase of advanced biologics therapy manufacturing campus in Longmont, Colorado worldpharmanews
April 02, 2019
AveXis further expanding AveXis' production capacity as it prepares to launch Zolgensma®...
Amgen, GSK, Novartis, BI spots head to the #FierceMadness Final Four fiercepharma
April 02, 2019
It's down to the Final Four in the #FierceMadness 2019 ad campaign tournament.
Did Novartis hand out kickbacks or host educational dinners? A jury may decide fiercepharma
April 02, 2019
Details that sound pulled from an episode of Billions are key accusations in a federal lawsuit against Swiss drugmaker Novartis that could face a jury trial after a district judge's order Monday.
Novartis' MS drug gets FDA approval pharmatimes
March 28, 2019
The US Food and Drug Administration (FDA) has approved Novartis’ Mayzent (siponimod) tablets to treat adults with relapsing forms of multiple sclerosis (MS).
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease worldpharmanews
March 28, 2019
Novartis today announced that the US Food and Drug Administration (FDA) has approved Mayzent® (siponimod) for the treatment of adults with relapsing forms of multiple sclerosis
Novartis’ internal probe, expert panel find no suspicious payments to Greek officials fiercepharma
March 23, 2019
Is the allegation that Novartis made dubious payments to top-ranking Greek officials a political witch hunt ……
Novartis joins the Global Chagas Disease Coalition and also announces first multinational, prospective, randomized study in people with chronic Chagas cardiomyopathy worldpharmanews
March 19, 2019
At the Annual Meeting of the Global Chagas Disease Coalition in Barcelona, Spain, Novartis announced that it is joining the Coalition as a member contributor.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page